Literature DB >> 9144290

Decay characteristics of HIV-1-infected compartments during combination therapy.

A S Perelson1, P Essunger, Y Cao, M Vesanen, A Hurley, K Saksela, M Markowitz, D D Ho.   

Abstract

Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1). The concentration of HIV-1 in plasma drops by approximately 99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of < or =6 hours and loss of productively infected cells with a t1/2 of 1.6 days. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2 of 1-4 weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5-2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3-3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144290     DOI: 10.1038/387188a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  570 in total

1.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  A simple relationship between viral load and survival time in HIV-1 infection.

Authors:  R A Arnaout; A L Lloyd; T R O'Brien; J J Goedert; J M Leonard; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro.

Authors:  C McCoig; G Van Dyke; C S Chou; L J Picker; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Comparative evaluation of two branched-DNA human immunodeficiency virus type 1 RNA quantification assays with lower detection limits of 50 and 500 copies per milliliter.

Authors:  C Manegold; C Krempe; H Jablonowski; L Kajala; M Dietrich; O Adams
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

Authors:  G P Rizzardi; R J De Boer; S Hoover; G Tambussi; A Chapuis; N Halkic; P A Bart; V Miller; S Staszewski; D W Notermans; L Perrin; C H Fox; J M Lange; A Lazzarin; G Pantaleo
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

6.  Benchmarks for antiretroviral therapy.

Authors:  O J Cohen; A S Fauci
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

7.  Virus load and sequence variation in simian retrovirus type 2 infection.

Authors:  L L Rosenblum; R A Weiss; M O McClure
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 9.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

10.  Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

Authors:  N M Ferguson; F deWolf; A C Ghani; C Fraser; C A Donnelly; P Reiss; J M Lange; S A Danner; G P Garnett; J Goudsmit; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.